When it came to the study’s secondary endpoints of survival, Telix pointed to a median overall survival (OS) rate of 12.4 ...

The quest for more effective cancer radiotherapy continues apace, with Telix Pharmaceuticals (ASX:TLX) today reporting “encouraging” preliminary results from its phase II study to treat recurrent high ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase ...

Telix Pharmaceuticals Limited, today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 in recurrent ...

Dr. David N. Cade, Telix Group Chief Medical Officer, said, “Telix will feature i MELBOURNE, Australia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq ...

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the ...

MELBOURNE, Australia and INDIANAPOLIS, April 15, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase ...

These results also potentially support higher therapeutic doses in subsequent prospective controlled studies.” Dr. David Cade, Chief Medical Officer at Telix, said, “These are encouraging results, ...